Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atea Pharmaceuticals advances COVID-19 treatment, diversifies programs for growth

Atea Pharmaceuticals showcased strong performance in clinical development and financial stability, with a focus on addressing COVID-19 therapy limitations.
While challenges exist in deprioritizing the Dengue program, opportunities in other antiviral programs and strategic shifts offer avenues for growth.
The company's extended cash guidance to 2026 reflects adaptability to changing priorities and a commitment to long-term success.

Atea Pharmaceuticals excels in Q1 2023, poised for growth

Atea Pharmaceuticals demonstrated strong financial performance and progress in their COVID-19 and HCV programs in Q1 2023.
The company's robust cash balance, operational excellence, and promising drug profiles highlight their competitive position.
While facing challenges in regulatory environments and clinical trial execution, Atea has opportunities for growth and market expansion.
Overall, Atea Pharmaceuticals remains well-positioned for future success with a focus on innovation and strategic partnerships.

Atea Pharmaceuticals reports strong Q2 earnings, eyes growth in antiviral treatments

Atea Pharmaceuticals demonstrated financial stability and progress in their antiviral programs, particularly in COVID-19 and hepatitis C treatments. While challenges with COVID-19 mutations persist, the company's focus on innovative treatments and potential partnerships signal a promising future in the antiviral market.

Atea Pharmaceuticals excels in antiviral programs, eyes multibillion-dollar market

Atea Pharmaceuticals demonstrated strong performance in Q3 2023, leveraging their expertise in antiviral therapeutics to address critical healthcare challenges. While challenges such as trial enrollment and market competition exist, the company is well-positioned to capitalize on the growing demand for innovative antiviral treatments.

Atea Pharmaceuticals excels in drug development, eyes growth opportunities

Atea Pharmaceuticals is making significant strides in drug development, particularly in COVID-19 and HCV programs. With a strong financial position and a focus on addressing unmet medical needs, the company is poised for future growth and success.

Atea Pharmaceuticals reports robust Q1 earnings, highlights bemnifosbuvir potential

Atea Pharmaceuticals showcased strong financial stability and promising developments in its COVID-19 and HCV programs during the Q1 2024 earnings call. While facing challenges in trial enrollments and regulatory pathways, the company remains well-positioned to capitalize on market opportunities and deliver value through innovative treatments.

Atea Pharmaceuticals reports strong Q2 earnings and advances HCV treatments

Atea Pharmaceuticals is well-positioned with strong operational performance, a promising HCV treatment pipeline, and a solid financial foundation. Navigating industry competition and successfully advancing Phase III trials will be key challenges, but the company has opportunities to solidify its position as a leader in HCV treatment.

Atea Pharmaceuticals excels in Q3 with promising HCV program

Atea Pharmaceuticals demonstrated strong performance in Q3 2024, with promising trial results and a solid financial position.
The company's HCV program shows great potential for addressing unmet medical needs and driving future growth.
While facing challenges in trial design and market competition, Atea remains confident in its ability to innovate and succeed in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Atea Pharmaceuticals Inc. AVIR, -68.50% took a 70.7% nosedive on heavy volume toward a record low in morning trading Tuesday, after the biopharmaceutical company said a Phase 2 trial of its oral treatment of SARS-CoV-2 virus in an outpatient setting failed to meet its primary endpoint. Trading volume swelled to 21.6 million shares, compared with the full-day average of about 2.7 million shares.

Atea Pharmaceuticals stock rocked after disappointing trial results of SARS-CoV-2 pill

(Reuters) -A mid-stage trial testing Atea Pharmaceuticals' COVID-19 treatment failed to meet the main goal of reducing the amount of SARS-CoV-2 virus in non-hospitalized patients with mild or moderate disease, the company said on Tuesday.

Atea Pharma's COVID-19 treatment fails to meet study goal; shares plunge

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. Related:   Atea Unveils Trial Amendments, New Data For COVID-19 Program.

Why Are Atea Pharmaceuticals Shares Plunging Today?

Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms

Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting

Ionis Pharma

Merck

These stocks could be attractive at discounted prices.

3 Stocks to Consider if the October Stock Market Sell-Off Worsens

Doximity

10X Genomics

Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic.

3 COVID Stocks That Can Turn $1,000 Into $10,000

Pfizer

Merck, Pfizer, and Atea are set to do battle next year in the COVID-19 pill market.

Which COVID-19 Pill Stock Is the Best Buy?

Ocugen, Inc.

Atea Pharmaceuticals and Ocugen may be gearing up for a stellar October.

2 Best Biotech Stocks to Buy In October

Are we seeing a major shift into oral medications for COVID? Our Foolish roundtable picks three of the strongest stocks in this rising subsector.

3 Stocks That Might Soar With Pills for COVID

This biotech's experimental COVID-19 medication could be a big winner.

Why Atea Pharmaceutical Stock Is Ripping Higher Today

The stock price of Atea Pharmaceuticals Inc (NASDAQ: AVIR) increased by over 25% pre-market today. This is why it happened.

AVIR Stock: Why It Substantially Increased Today

BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Tuesday, October 5, 2021 at 9:30 a.m. ET.

Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference

Orally administered treatments of COVID-19 infections are coming into focus as vaccine stocks lose their luster.

Why Atea Pharmaceuticals Is Up 17% Today

Histogen

NeuroBo Pharmaceuticals Inc

InVivo Therapeutics

Provention Bio Inc

Synthetic Biologics

Seqll

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 2:00 p.m. ET.

Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy. The article titled, “Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses,” can be accessed here. The published data demonstrate that AT-752 has potent in vitro activity against multiple dengue virus serotypes and other flaviviruses tested, and reduces viremia and improves survival in an animal model of dengue disease.

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752's Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q2 2021 Results - Earnings Call Transcript

Johnson & Johnson

Moderna

Sorrento Therapeutics Inc

Vaxart

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught appeared first on InvestorPlace.

7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide a clinical and corporate update.

Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021

An effective oral antiviral therapy for the coronavirus may be around the corner.

This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money

BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea together with other members of the Atea management team, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 12:00 p.m. ET.

Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19.  Roche Holding AG (OTC: RHHBY) and Atea jointly develop AT-527, an oral direct-acting antiviral agent derived from Atea's purine nucleotide prodrug platform.

Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG (OTC: RHHBY) of $50 million. Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19.

Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche

Milestone in the amount of $50 million realized Milestone in the amount of $50 million realized

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences.

News for Atea Pharmaceuticals Stock (AVIR)